Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Gallbladder01:17

Gallbladder

1.3K
The gallbladder is a small, pear-shaped organ that plays a crucial role in our digestive system. Measuring about 10 cm in length, it is comparable in size to a kiwi fruit and is located in a hollow area on the lower surface of the liver. The gallbladder's primary function is to store and concentrate bile, a fluid produced by the liver that aids in digestion.
The gallbladder's anatomy consists of three regions: the fundus, body, and neck. Extending from the neck, the cystic duct joins...
1.3K
Gastritis-I: Introduction and Types01:27

Gastritis-I: Introduction and Types

1.4K
Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
1.4K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

14.9K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.9K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

825
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
825
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

719
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
719
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

2.4K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
2.4K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The OMERACT core domain sets for calcium pyrophosphate deposition disease.

Seminars in arthritis and rheumatism·2026
Same author

Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in calcium pyrophosphate crystal deposition (CPPD).

Annals of the rheumatic diseases·2026
Same author

Retrospective Assignment to Study Groups Lowers More Than Urate Levels.

JAMA internal medicine·2026
Same author

OA fundamentals series: Diagnosis and clinical assessment of osteoarthritis.

Osteoarthritis and cartilage·2026
Same author

A Return to Normality: A Descriptive Qualitative Interview Study Exploring the Patient Experience of Gout Flare Resolution.

Arthritis care & research·2026
Same author

Fragility fracture, atypical femoral fracture, and osteonecrosis of jaw after bisphosphonate prescription for three and five years, based on primary and secondary care data in England: nested case-control and cohort studies.

BMJ medicine·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Nov 10, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K

痛風

Nicola Dalbeth1, Anna L Gosling2, Angelo Gaffo3

  • 1Department of Medicine, University of Auckland, Auckland, New Zealand.

Lancet (London, England)
|April 2, 2021
PubMed
まとめ
この要約は機械生成です。

酸ナトリウム結晶の堆積によって引き起こされる治療可能な病気です. 長期にわたる尿酸低下療法は,発作を効果的に予防し,生活の質を改善します.

さらに関連する動画

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

4.1K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K

関連する実験動画

Last Updated: Nov 10, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K
Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

4.1K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K

科学分野:

  • リウマトロジ
  • クリスタル誘発性関節炎

背景:

  • 痛風は,単酸ナトリウム結晶の堆積によって引き起こされる一般的な炎症性関節炎です.
  • 尿酸の血清値が上昇した高尿血症は,痛風の発症の主な危険因子です.
  • 尿酸の血清ホメオスタシスは,GLUT9,URAT1,ABCG2を含む腎臓と腸の尿酸トランスポーターによって調節される.

研究 の 目的:

  • 痛風の病理生理学を見直し,結晶の堆積と炎症経路に焦点を当てました.
  • 尿酸輸送体の高尿血症と痛風の病原性における役割について議論する.
  • 尿酸を低減する長期療法の効果と,痛風の管理におけるサポートケア戦略を強調する.

主な方法:

  • 痛風の病理生理学,リスク要因,治療戦略に関する文献レビュー.
  • モノナトリウムウラート結晶の堆積と炎症反応のメカニズム (例えば,NLRP3炎症体,中性粒子の細胞外トラップ) の分析.
  • 尿酸を下げる治療法とケアモデルの患者への影響の評価

主要な成果:

  • モノナトリウムウレート結晶の堆積はNLRP3炎症体の活性化を引き起こし,痛風の発症を引き起こします.
  • 中性粒子の細胞外トラップは 痛風発作の解消段階に関与しています
  • 長期にわたる尿酸低下療法により結晶が溶解し,発火,トフィーが予防され,生活の質が改善されます.

結論:

  • 痛風は慢性で 治療可能な病気で 長期にわたる治療が必要です
  • 効果的な管理には,血清ウレート濃度を下げて結晶を溶解させる必要がある.
  • 看護師主導のプログラムなどの 統合されたケア戦略は 痛風の管理と患者の成果を向上させます